Table 3.
Pharmacodynamic end-points
| +B | −B | |||||
|---|---|---|---|---|---|---|
| Group | n | Mean (SEM) | Mean (SEM) | Mean ratio (95% CI) | P | |
| AOC (mg h−1 dl−1) | All | 41 | 55.55 (0.11) | 73.73 (0.11) | 0.75 (0.58, 0.98) | 0.033 |
| Rev− | 25 | 47.7 (0.17) | 70.7 (0.17) | 0.67 (0.48, 0.94) | 0.021 | |
| Rev+ | 16 | 70.25 (0.23) | 79.12 (0.23) | 0.89 (0.59, 1.33) | 0.557 | |
| GLUmax,red (mg dl−1) | All | 41 | 19.82 (0.08) | 24.17 (0.08) | 0.82 (0.67, 1.00) | 0.052 |
| Rev− | 25 | 17.68 (0.13) | 24.34 (0.13) | 0.73 (0.56, 0.94) | 0.015 | |
| Rev+ | 16 | 23.58 (0.18) | 24.01 (0.18) | 0.98 (0.72, 1.34) | 0.907 | |
| tGLUmax,red (min) | All | 41 | 123.4 (0.10) | 83.83 (0.10) | 1.47 (1.16, 1.86) | 0.002 |
| Rev− | 25 | 130.8 (0.15) | 92.84 (0.15) | 1.41 (1.04, 1.91) | 0.028 | |
| Rev+ | 16 | 112.9 (0.21) | 71.31 (0.21) | 1.58 (1.09, 2.30) | 0.017 |
All means are geometric means [exp(Least Squares Means)] based on anova model. +B, with administration of bronchodilator 30 min before inhalation of insulin; −B, without prior administration of bronchodilator; Rev−, subjects with FEV1 increase <12% at baseline; Rev+, group with FEV1 increase ≥12% at baseline.